Mnk1 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CGP 57380 | 522629-08-9 | sc-202993 | 5 mg | $172.00 | 6 | |
CGP 57380 acts as a selective inhibitor of Mnk1, showcasing unique binding dynamics that alter the enzyme's phosphorylation activity. Its interaction with the Mnk1 active site induces specific conformational shifts, impacting downstream signaling cascades. The compound's kinetic behavior reveals a competitive inhibition pattern, which modulates the translation of stress-responsive proteins. This nuanced regulation highlights its role in fine-tuning cellular responses to environmental stimuli. | ||||||
Cercosporamide | 131436-22-1 | sc-202095 sc-202095A | 500 µg 2.5 mg | $300.00 $1200.00 | 2 | |
Cercosporamide functions as a selective modulator of Mnk1, exhibiting distinct molecular interactions that disrupt the enzyme's catalytic efficiency. Its binding affinity leads to unique allosteric changes, influencing the phosphorylation of target substrates. The compound's reaction kinetics suggest a non-competitive inhibition mechanism, which alters the dynamics of protein synthesis pathways. This intricate modulation underscores its potential to affect cellular homeostasis and stress adaptation processes. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $51.00 $123.00 $178.00 | 11 | |
HHT acts as an indirect inhibitor of Mnk1 by modulating eukaryotic initiation factor 4E (eIF4E) phosphorylation. It inhibits protein synthesis by interfering with the interaction between eIF4E and the mRNA cap, indirectly suppressing Mnk1 activity. | ||||||
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | 315706-13-9 | sc-202597 | 10 mg | $260.00 | 14 | |
4EGI-1 serves as an indirect inhibitor of Mnk1 by disrupting the eIF4E-eIF4G interaction, preventing the assembly of the eIF4F complex. By inhibiting the formation of this complex, 4EGI-1 indirectly suppresses Mnk1 activity, as Mnk1 phosphorylates eIF4E, a component of the eIF4F complex. | ||||||
Ro-32-0432 | 145333-02-4 | sc-3549 sc-3549A | 1 mg 5 mg | $103.00 $388.00 | 13 | |
Ro 32-0432 serves as an indirect inhibitor of Mnk1 by targeting protein kinase C (PKC). Activation of PKC by Ro 32-0432 leads to the inhibition of eIF4E phosphorylation by Mnk1, providing an indirect mechanism to suppress Mnk1 activity. | ||||||
A-443654 | 552325-16-3 | sc-507339 | 1 mg | $140.00 | ||
A-443654 serves as a direct inhibitor of Mnk1 by targeting its ATP-binding site. By binding to the kinase domain, this compound disrupts ATP binding, leading to the inhibition of Mnk1 catalytic activity. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 acts as a direct inhibitor of Mnk1 by targeting its ATP-binding site. Through binding to the kinase domain, this compound disrupts ATP binding, leading to the inhibition of Mnk1 catalytic activity. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
Halofuginone indirectly inhibits Mnk1 by modulating the unfolded protein response (UPR) pathway. By inducing endoplasmic reticulum (ER) stress, halofuginone triggers the PERK-eIF2α-ATF4 pathway, leading to the suppression of Mnk1 activity. | ||||||